loading page

Vaccination with COVID-19 mRNA-1273 is not associated with HIV-RNA blips among people with HIV on ART: a retrospective cohort study
  • +11
  • Andrea Lombardi,
  • Giorgio Bozzi,
  • Giulia Viero,
  • Cecilia Azzarà,
  • Valeria Castelli,
  • Susanna Scaglioni,
  • Giacomo M. Butta,
  • Antonio Muscatello,
  • Serena Ludovisi,
  • Ferruccio Ceriotti,
  • Patrizia Bono,
  • Andrea Gori,
  • Lara Manganaro,
  • Alessandra Bandera
Andrea Lombardi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Corresponding Author:[email protected]

Author Profile
Giorgio Bozzi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Giulia Viero
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Cecilia Azzarà
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Valeria Castelli
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Susanna Scaglioni
Universita degli Studi di Milano
Author Profile
Giacomo M. Butta
Universita degli Studi di Milano
Author Profile
Antonio Muscatello
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Serena Ludovisi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Ferruccio Ceriotti
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Patrizia Bono
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Andrea Gori
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile
Lara Manganaro
Universita degli Studi di Milano
Author Profile
Alessandra Bandera
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Author Profile

Abstract

Objectives: Viral blips (VB) have been reported in people with HIV (PWH) after COVID-19 vaccination. Materials and Methods: We performed a retrospective cohort study among virally suppressed PWH vaccinated against COVID-19 with mRNA-1273, comparing the occurrence of VB in the 12 months after the first vaccine shot with those recorded in the 12 months before. The association between several clinical and immunologic variables and VB have been evaluated through logistic regression. Results: Overall, 48 individuals were included in our analysis. No difference was recorded between VB incidence in the 12 months before and after vaccination [11/48 (23%) vs 15/48 (31.3%), p=0.42]. No significant association was detected between selected variables and VB occurrence after vaccination. In a post hoc analysis including also 8 PWH excluded for not reaching the definition of viral suppression, we observed 15 increases of HIV RNA out of 56 PWH (26.8%) before vaccination and 23 increases of HIV RNA out of 56 PWH after vaccination (41.1%). This difference in incidence remained not significant (p=0.10) but a strong association between increases of HIV RNA occurrence before and after vaccination [p=0.02, OR 4.3 (95% CI 1-22-15.17)] was found. Conclusion: Among virally suppressed PWH, COVID-19 vaccination with mRNA-1273 is not associated with increased occurrence of VB.